Purpose Thromboembolism is a major source of morbidity and mortality in patients with
cancer. The contribution of anti–vascular endothelial growth factor therapy to these events …

Cancer and its treatments are well-recognized risk factors for venous thrombo-embolism
(VTE). Although solid tumors have historically been associated with VTE, more recent data …

Purpose Anticancer agents are known to increase cancer-associated thrombosis (CAT)
onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel …

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in
the past decade, possibly due to novel cancer therapies, improved survival, and high …

Opinion statement Vascular events have become an important issue in the overall
management of cancer patients. They usually result from a combination of (i) direct or …

Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Nearly 20% of all venous thromboembolism (VTE) occurs in cancer patients, and as many
as 78% of cancer patients who develop a thrombotic event do so as outpatients. The risk of …

Abstract Background Venous (VTEs) and arterial thromboembolic events (ATEs) are causes
of morbidity, disability, mortality, and increase in treatment costs in cancer patients. The risk …

Malignancy has long been implicated with hypercoagulability, leading to an increased rate
of both venous and arterial thromboembolic events (VTE and ATE). Immunotherapy has …

Cancer-related venous thromboembolism (VTE) remains a major health problem,
accounting for at least 18% of all cases of VTE. Cancer patients with VTE have worse …